Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

Nyhedsbrev marts 2020

OMF 2019 Årsrapport

Vi er klar over, at I tager jeres filantropi alvorligt og vi er beærede over, at I tror på vores mission og vores anstrengelser for at gøre en ende på ME / CFS. Resultaterne i den følgende OMF 2020 årsrapport, er kun positive på grund af jer; jeres investering i vores arbejde og jeres tro på vores fælles vision om en verden fri for ME / CFS. Ord er ikke tilstrækkelige til at beskrive vores taknemmlighed…

OMF 2019 Årsrapport
Organisatoriske resultater

Vi har sagt velkommen til:

  • Nye medlemmer af videnskabelige råd (SAB): Alain Moreau, PhD og Michael Snyder, PhD
  • Ny medicinsk chef: Ronald Tompkins, MD, ScD
  • Ny VP for filantropi: Kathleen Morgen
  • Nye ambassadører: Karin Alvtegen and Jaqueline Ko

Vi har også:

  • Lanceret et nyt ME / CFS Collaborative Research Center på Uppsala University i Sverige
  • Sponsoreret to udbytterig forsknings symposier på Stanford og Harvard
  • Sponsereret 2 community symposier
  • Leveret gratis live streaming fra Stanford Community symposium
  • Finansieret avanceret forskning for talrige projekter
  • Etableret OMF Canada
  • Samlet klinikere med tilknytning for at udforske nye muligheder for samarbejde mellem specialister

ME / CFS Collaborative Research Center opdatering

Jeres 2019 bidrag har finansieret åben og samarbejdende forskning over hele kloden, udført efter upåklagelige standarder og med integritet af forskere og klinikere af højeste kaliber.

 


STANFORD UNIVERSITY COLLABORATIVE RESEARCH CENTER

Under ledelse af Ronald W. Davis, PhD,
Professor i Biochemistry og Genetics

Open Medicine Foundation has been the lead funding partner of Dr. Davis’s ME / CFS research at Stanford University since 2014.

2019 forsknings fokus:

  • Udvikling af nanonål teknologi
  • Teknologi til at måle røde blodlegmeres deformerbarhed
  • Tryptofan metaolisk fælde
  • Bestemmelse af spor tungmetaller
  • Udvikling af en ny test til at udvidde antallet af patogener der kan bestemmes celle fri DNA/RNA

Direkte DNA sekventering af gener med mulig forbindelse til ME / CFS

2019 publikationer inkluderer:

Please visit our website for more information about projects at the Stanford CRC

Read Stanford’s Year-End Message

 


HARVARD AFFILIATED HOSPITALS COLLABORATIVE RESEARCH CENTER

Under fælles ledelse af Ronald G. Tompkins, MD, ScD
Sumner M. Redstone Professor i kirurgi, Harvard Medical School Founding Director

 

 

 

 

Under fælles ledelse af Wenzhong Xiao, PhD
Assisterende professor i Bioinformatic og Director af Inflammation & Metabolism Computational Center ved Massachusetts General Hospital

I 2018 lancerede OMF finansieringen af et partnerskab med Harvard tilknyttede hospitaler, bl.a. Massachusetts General Hospital (MGH), Brigham and Women’s Hospital (BWH), and Beth Israel Deaconess Medical Center (BIDMC).

Dette forskningssamarbejde søger vha. forskningsstudier og kliniske studier, at karakterisere de dynamiske biologiske forandringer der optræder under ændringer af symptombilledet for ME / CFS patienter.

Projekter lanceret i 2019 inkluderer:

  • BWH iCPET biorespiratoriske plasma proteonomiske og metabolomiske studier
  • PASS/CAT udvikling af diagnostisk redskab
  • Symposiums, Forskning og Community

Besøg vores website for mere information om projekter på Harvard CRC

 


UPPSALA UNIVERSITY, SWEDEN COLLABORATIVE RESEARCH CENTER

Under ledelse af  Jonas Bergquist, MD, PhD
Full Chair Professor in Analytical Chemistry and Neurochemistry

I 2019 finansierede og lancerede OMF endnu et ME / CFS Collaborative Research Center denne gang på Uppsala University under ledelse af Jonas Bergquist, MD, PhD.

Det nye center fokuserer på målrettet molekylær diagnose af ME / CFS med det formål at opnå evidens-baseret strategi for intervention.

Nuværende projekter inkluderer:

  • Kynurenine studier i ME / CFS
  • Autoimmunitets aspekter af ME / CFS
  • Endokrine hormon forstyrelser i ME / CFS

Besøg vores website for mere information om projeker på Uppsala CRC

 


Vi er stolte af, at vi i 2019 blev optaget i Great Nonprofits,
og at have opnået Platinum anerkendelse fra GuideStar
for vores bestræbelser for at at være en transperant organisation.

Vi ser frem til 2020 med Håb for Alle

 

OMF thanks Pia for this translation.

 

 

 

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo